Desert Sun readers sound off on President Donald Trump, USAID, a Desert Sun longtime-columnist in today's letters to the ...

Disney is hosting a Hollywood premiere of “Snow White” on March 15, but the studio won’t be rolling out a robust red carpet ...

Announced in the company’s Q4 earnings call, lupus drug enpatoran failed to meet the primary endpoint of British Isles Lupus Assessment Group (BILAG)-Based Composite Lupus Assessment (BICLA ...

It will also pay milestone payments of up to $1.875 billion to Gubra. FDA Accepts Roche’s Gazyva sBLA for Lupus Nephritis The FDA accepted a supplemental biologics license application (sBLA ...

Lana is a stunning 1-year-old Shepherd girl with a heart full of adventure, and she’s ready to find her forever home!

Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of ...

Rose, 40, has been living with lupus for the past 17 years. Her condition frequently impacts her daily life significantly. “I never really thought about buying a smartwatch. I have to prioritize my ...

Kathy is an old gal who could stand to lose a few pounds. Sound like anyone you know? If so, they might make a great team!

CB-010, a clinical-stage allogeneic anti-CD19 CAR-T cell therapy for lupus Caribou continues to activate sites for the GALLOP Phase 1 clinical trial, an open-label, multicenter clinical trial ...

ESK-001 is a next-generation oral tyrosine kinase 2 (TYK2) inhibitor in development for moderate-to-severe plaque psoriasis and systemic lupus. ESK-001 was generally well-tolerated over one year ...

ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque psoriasis and systemic lupus Phase 2 OLE data of ESK ...